Octave Bioscience, Inc announced that it is advancing development of the world’s first biomarker blood test for MS progression with support from the Valhalla Foundation.
The grant will fund the identification of individual proteins and the development of multi-analyte biomarker models, advancing the Multiple Sclerosis Disease Progression (MSDP) Test toward commercial viability as a complementary solution to Octave’s MS Disease Activity (MSDA) Test, the first validated AI-enabled multi-protein blood test for MS. In collaboration with leading academic partners worldwide, Octave will use advanced assays to study proteins in MS patients, with findings to be published in a leading peer-reviewed journal.
MSDP Test addresses one of the most urgent unmet needs in MS: the lack of reliable tools to measure or predict progression. Today, physicians and patients must rely on subjective assessments and infrequent imaging, leaving critical changes undetected until disability has advanced. Octave’s test will combine multi-protein biomarkers with AI-driven algorithms to deliver objective scores that track progression over time, empowering physicians to make earlier, more confident treatment decisions. Delivered as a simple blood test, the MSDP Test is being designed for all MS patients including Relapsing Remitting MS (RRMS), Primary Progressive MS (PPMS), and Secondary Progressive MS (SPMS).
